Oncternal Therapeutics (NASDAQ:ONCT) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a report published on Monday morning. The firm issued a sell rating on the stock. Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald reiterated a neutral rating and issued a $1.30 target price on shares of Oncternal […]
More Stories
Iran Says It Has Some Details of US Proposal for New Nuclear Deal
By Ryan Morgan Iranian Foreign Minister Abbas Araghchi has seen some of the first details of a U.S.-drafted proposal for...
Wexford Capital LP Buys New Shares in NVIDIA Co. (NASDAQ:NVDA)
Wexford Capital LP bought a new position in shares of NVIDIA Co. (NASDAQ:NVDA – Free Report) during the 4th quarter,...
Best Streaming Stocks To Keep An Eye On – May 30th
NVIDIA, AppLovin, Spotify Technology, Live Nation Entertainment, and Walt Disney are the five Streaming stocks to watch today, according to...
Infrastructure Stocks Worth Watching – May 30th
NVIDIA, Alphabet, and Broadcom are the three Infrastructure stocks to watch today, according to MarketBeat’s stock screener tool. Infrastructure stocks...
Two Sigma Investments LP Cuts Position in Academy Sports and Outdoors, Inc. (NASDAQ:ASO)
Two Sigma Investments LP reduced its holdings in shares of Academy Sports and Outdoors, Inc. (NASDAQ:ASO – Free Report) by...
Two Sigma Advisers LP Has $974.62 Million Position in Amazon.com, Inc. (NASDAQ:AMZN)
Two Sigma Advisers LP boosted its holdings in Amazon.com, Inc. (NASDAQ:AMZN – Free Report) by 121.7% in the 4th quarter,...